Gonzalo Revuelta, DO
Neurology · Charleston, SCNPI 1457520520
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Boston Scientific at 46.7% of the total. Reporting peaked in 2019 at $5,395 and has fallen 68.9% since, to $1,677 in 2025.
Across 57 payments — averaging $205.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Abbott$3K
- Insightec,inc$1K
- Amneal Pharmaceuticals LLC$1K
- Medtronic$476
- MDD US Operations, LLC$349
- plus $137 from 3 others
Across 17 payments — averaging $2650.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$45K
What the payments were for
- Consulting fees$6,12552%
- Speaking & faculty fees$1,0009%
- Travel & lodging$1,86616%
- Food & beverage$2,74823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $5,484 |
| Abbott | 13 | $3,020 |
| Insightec,inc | 8 | $1,273 |
| Amneal Pharmaceuticals LLC | 1 | $1,000 |
| Medtronic | 4 | $476 |
| MDD US Operations, LLC | 11 | $349 |
| Kyowa Kirin, Inc. | 1 | $103 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL DBS$4,178
- INFINITY$2,212
- Exablate$1,083
- GENERAL - THERAPIES$1,059
- RYTARY$1,000
- PERCEPT PC BRAINSENSE$428
- Infinity DBS Pulse Generators$310
- Proclaim IPG$128
- NOURIANZ$103
How this compares
$11,739 in reported general payments places this provider in the 80th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GocovriAmantadine Hcl | 112 | $396,904 |
| RytaryCarbidopa/Levodopa | 128 | $342,805 |
| NourianzIstradefylline | 51 | $134,648 |
| NuplazidPimavanserin Tartrate | 14 | $99,028 |
| Droxidopa | 14 | $96,140 |
| Rasagiline Mesylate | 62 | $37,169 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 156 | $9,252 |
| Entacapone | 17 | $3,356 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 67 | $3,161 |
| Tetrabenazine | 11 | $2,046 |
| AmantadineAmantadine Hcl | 48 | $1,822 |
| Ropinirole Hcl | 29 | $1,420 |
| Donepezil Hcl | 73 | $1,052 |
| Primidone | 38 | $1,044 |
| Midodrine Hcl | 19 | $985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $349 | $396,904112 claims |
| Amneal Pharmaceuticals LLCRytary | $1,000 | $342,805128 claims |
| Kyowa Kirin, Inc.Nourianz | $103 | $134,64851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 270 neurology providers in South Carolina.
Other neurology in Charleston
- Robert AdamsCharleston$204K
- Sarah BreevoortCharleston$90K
- Tanya TuranCharleston$77K
- Katherine RuzhanskyCharleston$52K
- Jonathan HalfordCharleston$48K
- Andrew KeeganCharleston$48K
- Aljoeson WalkerCharleston$35K
- Hamid BahadoriCharleston$29K
- Bruce OvbiageleCharleston$27K
- Andrew AmeriCharleston$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.